Novo Nordisk announced topline results showing CagriSema, a fixed-dose combination of cagrilintide and semaglutide, produced greater weight loss than tirzepatide in adults with type 2 diabetes in the REIMAGINE 5 trial (12.4% vs. 9.1% at 60 weeks), while achieving noninferior HbA1c reductions. In the REDEFINE 9 trial, CagriSema led to 21% weight loss at 68 weeks in adults with overweight or obesity without diabetes. These are topline company-announced results from ongoing trial programs.
The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.